October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole doesn't work.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Focus on general hair care and lifestyle changes.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Focus on general hair care and lifestyle changes.
This article discusses hair loss disorders, underscoring the recent therapeutic advance of ritlecitinib, approved for severe alopecia areata in individuals aged 12 and older, and the ongoing need to manage expectations given limited treatment options.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.
